Vicarious Surgical Inc.: directors' dealings · United States · SEC (Form 4)

About Vicarious Surgical Inc.

Vicarious Surgical Inc. is a U.S.-based medical robotics company listed on the American market, specifically associated with the NYSE/NASDAQ universe through ticker RBOTW, and headquartered in Waltham, Massachusetts, United States. The company was founded in 2014 and is developing a next-generation surgical robotics platform focused on minimally invasive procedures. From an equity research perspective, Vicarious Surgical is best viewed as a disruptive early-stage medtech developer trying to challenge the economics and usability of established robotic surgery systems. Its strategic goal is to expand access to robotic surgery while improving procedural efficiency and, ultimately, helping lower healthcare costs. ([investor.vicarioussurgical.com](https://investor.vicarioussurgical.com/overview/?utm_source=openai)) The company’s core business is the design and advancement of a proprietary surgical robot rather than a mature, scaled commercial franchise. That matters for investors: the story is driven less by current sales and more by product development milestones, clinical validation, regulatory progress, capital discipline, and eventual hospital adoption. In other words, Vicarious Surgical carries the hallmark risk/reward profile of an early commercial or pre-commercial healthcare robotics name. Upside depends on proving that its system can deliver differentiated clinical and economic value in real-world operating environments. ([investor.vicarioussurgical.com](https://investor.vicarioussurgical.com/overview/?utm_source=openai)) Competitively, the company operates in a market led by much larger and better-capitalized players, most notably Intuitive Surgical. Vicarious Surgical is trying to stand out through a different robotics architecture and a value proposition centered on better dexterity, improved visualization, enhanced surgeon ergonomics, and potentially lower total procedure cost. That disruptive positioning is interesting, but it also means execution risk is high. The market will want to see evidence of engineering readiness, repeatable performance, safety, and a credible pathway to commercialization before assigning a durable premium valuation. ([investor.vicarioussurgical.com](https://investor.vicarioussurgical.com/overview/?utm_source=openai)) Geographically, the business is primarily U.S.-centered, with its headquarters and principal corporate presence in Massachusetts. Public disclosures and investor communications indicate that the company remains focused on the United States for its core operations and capital-markets outreach. The company’s investor relations materials, earnings releases, and conference participation also suggest a narrative still anchored in development and financing rather than broad international sales. That is typical for a robotics platform company at this stage of its lifecycle. ([investor.vicarioussurgical.com](https://investor.vicarioussurgical.com/overview/?utm_source=openai)) Recent updates through 2025 and 2026 have emphasized cash burn management, quarterly financial results, and ongoing engagement with the investment community. Those disclosures are important because they frame the company’s near-term priorities: preserving liquidity, advancing the platform, and maintaining optionality for future commercialization. Insider Form 4 activity has also been visible in the market, which often draws attention among small-cap investors trying to gauge management sentiment. Overall, RBOTW remains a speculative healthcare robotics name tied to technology execution, financing needs, and the company’s ability to convert a promising concept into a commercially viable surgical system. ([stocktitan.net](https://www.stocktitan.net/sec-filings/RBOT/form-4-vicarious-surgical-inc-insider-trading-activity-bd58b7e8dadf.html?utm_source=openai))